Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 1
2012 1
2013 1
2019 1
2020 7
2021 4
2022 6
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Acute myeloid leukemia in SRP54-mutated congenital neutropenia.
Sabulski A, Grier DD, Myers KC, Davies SM, Rubinstein JD. Sabulski A, et al. Among authors: rubinstein jd. EJHaem. 2022 Mar 16;3(2):521-525. doi: 10.1002/jha2.413. eCollection 2022 May. EJHaem. 2022. PMID: 35846055 Free PMC article.
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM. Ceolin V, et al. Among authors: rubinstein jd. Leukemia. 2023 Jan;37(1):53-60. doi: 10.1038/s41375-022-01740-9. Epub 2022 Oct 30. Leukemia. 2023. PMID: 36310183
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD, Breese EH, Krupski MC, O'Brien MM, Dandoy CE, Mizukawa B, Khoury R, Norris RE, Davies SM, Phillips CL. Rubinstein JD, et al. Transplant Cell Ther. 2023 May;29(5):311.e1-311.e7. doi: 10.1016/j.jtct.2023.02.012. Epub 2023 Feb 19. Transplant Cell Ther. 2023. PMID: 36809824 Free article.
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YM, Hanley PJ, Keller MD, Bollard CM, Davies SM, Grimley MS, Rubinstein JD. Galletta TJ, et al. Among authors: rubinstein jd. Transplant Cell Ther. 2023 May;29(5):305-310. doi: 10.1016/j.jtct.2023.01.027. Epub 2023 Feb 3. Transplant Cell Ther. 2023. PMID: 36736781 Free article.
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray L, Thomas S, Dourson C, Wilhelm J, Lane A, Cancelas JA, Lipps D, Ferrell J, Hanley PJ, Keller MD, Bollard CM, Wang YM, Davies SM, Nelson AS, Grimley MS. Rubinstein JD, et al. Blood Adv. 2022 May 10;6(9):2897-2907. doi: 10.1182/bloodadvances.2021006309. Blood Adv. 2022. PMID: 35108727 Free PMC article. Clinical Trial.
Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM, Taj MM, Orjuela-Grimm M, Srivatsa K, Miller TP, Edington HJ, Dalal M, Robles J, Ford JB, Ehrhardt MJ, Ureda TJ, Rubinstein JD, McCormack S, Rivers JM, Chisholm KM, Kavanaugh MK, Bukowinski AJ, Friehling ED, Ford MC, Reddy SN, Marks LJ, Smith CM, Mason CC. Afify ZAM, et al. Among authors: rubinstein jd. Cancer. 2023 Mar 1;129(5):780-789. doi: 10.1002/cncr.34600. Epub 2022 Dec 26. Cancer. 2023. PMID: 36571557 Free article.
28 results